1 Subjects: “...Canada...”

2 Subjects: “...Canada...”

3 “... product derivative -- in Canada. This assessment compliments a set of clinical and cost-effectiveness...”

4 “... product derivative -- in Canada. This assessment compliments a set of clinical and cost-effectiveness...”

5 “... receptor (CAR) T-cell therapy to be approved in Canada. Following a priority review, Health Canada approved...”

6 “..., and is pending approval from Health Canada. Where approved, it is indicated for patients with eligible subtypes...”